After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Dyne Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Dyne Therapeutics Inc is $2.99B. A total of 2.1 million shares were traded on the day, compared to an average of 2.65M shares.
In the most recent transaction, Cox John sold 2,640 shares of DYN for 13.41 per share on Sep 05 ’25. After the transaction, the CEO & President now owns 199,539 company shares. In a previous transaction on Sep 04 ’25, Friedl-Naderer Johanna sold 894 shares at 13.27 per share. DYN shares that Chief Commercial Officer owns now total 95,017.
Among the insiders who sold shares, Friedl-Naderer Johanna disposed of 144 shares on Sep 05 ’25 at a per-share price of $13.41. This resulted in the Chief Commercial Officer holding 94,873 shares of DYN after the transaction. In another insider transaction, Kerr Douglas sold 3,552 shares at $13.27 per share on Sep 04 ’25. Company shares held by the Chief Medical Officer now total 89,263.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, DYN has a high of $31.32 and a low of $6.36.
As of this writing, DYN has an earnings estimate of -$0.77 per share for the current quarter. EPS was calculated based on a consensus of 11.0 estimates, with a high estimate of -$0.59 per share and a lower estimate of -$0.94. The company reported an EPS of -$0.88 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. DYN’s latest balance sheet shows that the firm has $376.57M in Cash & Short Term Investments as of fiscal 2021. There were $32.64M in debt and $28.72M in liabilities at the time. Its Book Value Per Share was $4.85, while its Total Shareholder’s Equity was $368.20M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DYN is Buy with a score of 4.50.
